A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients

Exclusion Criteria

• •Patients with valvular heart disease/congenital heart disease
• •Patients with ischemic heart disease/history of myocardial infarction/coronary artery bypass surgery
• •Patients with history of heart failure
• •Patients with regression line of 1/serum creatinine versus time showing that the estimated date of end stage renal disease is within 12 months
• •Patients with thalassemic trait or haemoglobinopathies
• •Patients with underlying haematological malignancies
• •Patients with active bleeding
• •Patients with uncorrected iron or other vitamins deficiencies
• •Patients with poor general condition